Discover
BackTable Urology
BackTable Urology
Author: BackTable Inc.
Subscribed: 71Played: 3,110Subscribe
Share
© All rights reserved.
Description
The BackTable Urology Podcast is a resource for practicing urologists to learn tips, techniques, and practical advice from their peers in the field. Listen here or on the streaming platform of your choice.
342 Episodes
Reverse
If you’ve felt penalized for getting faster in the OR, you’re not imagining it. On this episode of BackTable Urology, Dr. Ruchika Talwar interviews Dr. Kyle Richards, urologic oncologist at the University of Wisconsin and the American Urological Association's (AUA) representative on the RVS Update Committee (RUC), about how relative value units (RVUs) are set and who decides what a procedure is worth. Dr. Richards traces RVUs from their 1989 origins to the physician surveys behind every recommendation the RUC sends to Medicare, explains how a new technology earns a CPT code and a value, and shares why urology's single seat on the 31-member committee makes every survey response count.
---
Get the BackTable apphttps://www.backtable.com/app
---
This podcast was developed in collaboration with
Society of Urologic Oncologyhttps://suonet.org/home
---
Timestamps
00:00 - Introduction02:27 - What Is an RVU?05:31 - Who Decides What a Procedure Is Worth08:04 - How the RUC Works With CMS10:10 - New Technology and New CPT Codes13:32 - Inside the RUC Survey18:26 - Who Sits on the RUC and How It Votes22:08 - Budget Neutrality and the Conversion Factor25:04 - Is Efficiency Being Penalized?29:27 - New Codes for Retroperitoneal Cytoreduction33:09 - Prostate Biopsy Codes and Practice Expense36:47 - How Robotic Prostatectomy Has Been Valued45:46 - How Urologists Can Get Involved
---More about this episodeDr. Kyle Richards explains how shorter intra-service times, budget neutrality, and Medicare's recent efficiency adjustment push RVUs down as procedures get faster, why practice expense makes up nearly half of a procedure's total RVUs, and why publications that showcase the fastest surgeon can make an appeal harder. He highlights recent wins for urology, including new codes for retroperitoneal cytoreduction after chemotherapy and for fusion, MRI-guided, and transperineal prostate biopsy, and tells the full story of how robotic prostatectomy has been valued, cut, appealed, and bundled with lymph node dissection. His advice for urologists who want a voice is simple: fill out the RUC survey when it arrives, report honest operative times, and get involved through the AUA and state medical societies.
---
Resources
American Medical Association: RVS Update Committee (RUC)https://www.ama-assn.org/about/rvs-update-committee-ruc Fix Medicare Now (American Medical Association)https://fixmedicarenow.org Leow JJ, et al. Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database. Eur Urol. 2016https://doi.org/10.1016/j.eururo.2016.01.044 Hsiao WC, et al. Estimating physicians' work for a resource-based relative-value scale. N Engl J Med. 1988https://doi.org/10.1056/NEJM198809293191305
---
BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app
“No cancer patient ever got healthier because their claim was denied and delayed. None. Not one.” Mark Cuban's verdict will ring true for any urologist who has fought a denied or delayed claim, and his alternative is a contract that starts by trusting the doctor. On this episode of BackTable Urology, Dr. Ruchika Talwar, urologic oncologist and value-based care leader, talks with Mark Cuban, entrepreneur and founder of Mark Cuban Cost Plus Drug Company, about who actually sets the price of care in the United States. They trace how a cold email about drug shortages led to Cost Plus Drugs and then Cost Plus Wellness, an open source library of direct contracts between self-insured employers and providers, and why he believes the contract, not the published price, is where the real problems hide. By his estimate, 67% of people with job-based coverage get it through a self-insured employer, which makes employers, not insurers, the real payers in American healthcare.
---
Get the BackTable apphttps://www.backtable.com/app
---
Timestamps00:00 - Introduction01:53 - From Drug Shortages to Cost Plus Drugs06:08 - Cost Plus Wellness and Direct Contracts11:04 - Publishing Provider Contracts16:39 - Using AI to Review Contracts and RFPs20:16 - Direct Contracting Advice for Hospitals and Physicians26:33 - Value-Based Care, Brokers, and Self-Insured Hospitals32:09 - Direct Contracting for Independent Practices34:20 - AI as a Business Adviser for Physicians38:39 - National Policy and Who Pays for Healthcare46:59 - Misaligned Incentives and Corporate Culture51:00 - Key Takeaways54:04 - Closing Remarks
---
More about this episodeThe conversation then turns practical for physicians. Mark Cuban lays out how hospitals, clinics, and independent practices can find the self-insured employers among their own patients and offer direct contracts or carve-outs, why a promise to trust the doctor can earn employers a better rate, and how he runs contracts that stretch past a thousand pages through several AI models in turn. He and Dr. Talwar also cover what employers can learn from Form 5500 filings, the national changes he would make, from ending gag clauses to standardized public contracts, and why both see misaligned incentives as the root of the problem.
---
ResourcesMark Cuban Cost Plus Drug Companyhttps://costplusdrugs.com Cost Plus Wellness: an open source initiative by Mark Cubanhttps://costpluswellness.com Mark Cuban dives into direct contracting. Becker's Hospital Review. 2026https://www.beckershospitalreview.com/finance/mark-cuban-dives-into-direct-hospital-contracting/ Form 5500 filings search (EFAST2), U.S. Department of Laborhttps://www.efast.dol.gov/welcome.html KFF. 2025 Employer Health Benefits Surveyhttps://www.kff.org/health-costs/2025-employer-health-benefits-survey/ Gag Clause Prohibition Compliance Attestation. Centers for Medicare & Medicaid Serviceshttps://www.cms.gov/marketplace/about/oversight/other-insurance-protections/gag-clause-prohibition-compliance-attestation New generic drug company named after Mark Cuban first founded by a part-time radiologist. Health Imaginghttps://healthimaging.com/topics/healthcare-management/medical-practice-management/mark-cuban-generic-drug-company Dr. Ruchika Talwar, BackTable Urology contributor pagehttps://www.backtable.com/shows/urology/contributors/dr-ruchika-talwar
---BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.► https://www.backtable.com/app
Mid-career is the stretch when you are no longer the new person on the block, but not yet the one in charge, and it gets far less attention than the years on either side of it. On this episode of BackTable Urology, presented in collaboration with the Society of Women in Urology (SWIU), Dr. Michelle Van Kuiken talks with Dr. Debra Fromer and Dr. Anne Suskind, both urology division chiefs and faculty vice chairs, about what no one tells you about mid-career. They describe how to know you have arrived there, why boredom can be the clearest signal that it is time to change, and why mid-career is the moment to say yes to a leadership role you have never trained for, even if what you learn is that you do not like it.
---
Get the BackTable apphttps://www.backtable.com/app
---
This podcast was developed in collaboration with
Society of Women in Urologyhttps://swiu.org/home.aspx
---
Timestamps
00:00 - Introduction01:50 - Defining Mid-Career04:05 - Career as an Evolution07:21 - Plateaus, Boredom, and Burnout09:55 - Imposter Syndrome and New Leadership Roles11:37 - Traps That Stall Mid-Career Growth15:14 - Changing Expectations at Work and at Home18:17 - Redefining Success20:51 - Mentorship at Every Career Stage22:26 - Phasing Out and Legacy25:11 - Staying Motivated27:38 - Life Outside Work31:10 - Parting Words and Closing Remarks
---
More about this episode
The three surgeons then name the traps that stall growth, from support that falls away after the junior years to unrecognized, unpaid roles and the competing demands of young children and aging parents. Dr. Fromer explains why control over her own time has always been her measure of success, and Dr. Suskind makes the case for new mentors and peer mentors at every stage. They close on phasing out and legacy, what keeps them motivated, and how challenges outside the hospital, from leading a urology Battle of the Bands to tournament golf, can feed a career.
---
Resources
Society of Women in Urology (SWIU)https://www.swiu.org New York Section of the American Urological Associationhttps://www.nyaua.com Docs Who Rock Raise More than $10,000 for Important Urological Initiatives. HMH Maestro, 2025https://hmhmaestro.org/en/topics/featured-physicians/2025/04/21/docs-who-rock-raise-more-than-10000-for-important-urological-initiatives Dr. Michelle Van Kuiken, BackTable Urology contributor pagehttps://www.backtable.com/shows/urology/contributors/dr-michelle-van-kuiken
---
BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app
How many prostate medications and procedures should a man try before anyone checks his bladder? Dr. Bilal Chughtai has met men who worked through an alpha blocker, add-on medications, a minimally invasive prostate procedure, and even resective surgery before anyone named overactive bladder as part of the problem. On this episode of BackTable Urology, Dr. Anjali Kapur, urogynecologist at Hackensack Meridian Health, welcomes Dr. Chughtai, chief of urology at Northwell Health's Plainview and Syosset hospitals, to rethink how urologists separate overactive bladder (OAB) from benign prostatic hyperplasia (BPH) in men. Dr. Chughtai explains how he reads the storage and voiding items of the International Prostate Symptom Score (IPSS), why he usually starts with a beta-3 agonist rather than an anticholinergic, how he trims polypharmacy one medication holiday at a time, and when urodynamics helps decide whether to treat the prostate, the bladder, or both.
---
Get the BackTable apphttps://www.backtable.com/app
---
This podcast is supported by
Sumitomo Pharma America, Inc.https://www.us.sumitomo-pharma.com/
---
Timestamps
00:00 - Introduction02:37 - Initial Evaluation and First-Line Therapy06:11 - Combination Therapy and Medication Holidays09:37 - Reassessing Symptoms After an Outlet Procedure11:59 - Botox and Neuromodulation in Men15:14 - Persistent Symptoms After Prior BPH Treatment18:44 - The COURAGE Trial and Urge Incontinence23:22 - Combining Therapies and Setting Goals25:48 - Questionnaires, Bladder Diaries, and Underreporting29:05 - OAB Awareness in Primary Care31:14 - Nocturia and Sleep Apnea33:23 - Timing of Intervention and Bladder Health38:04 - Final Takeaways and Closing Remarks
---
More about this episode
The two then turn to third-line therapy in men, including intradetrusor botulinum toxin, sacral neuromodulation, and tibial nerve stimulation, and to men whose storage symptoms persist or appear after an outlet procedure. Dr. Chughtai shares what the COURAGE trial of a beta-3 agonist added to BPH therapy taught him about asking men directly about urge incontinence, along with his goal of a 50% improvement in symptoms, the limits of questionnaires and bladder diaries, his research on OAB awareness in primary care, and the link between nocturia and sleep apnea. They close on the open question of when to treat the bladder before it changes, and why counseling should inform men without threatening them.
---
Resources
Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial. J Urol. 2024https://pubmed.ncbi.nlm.nih.gov/38708869/ Vibegron for overactive bladder in men with benign prostatic hyperplasia/obstruction: insights from the COURAGE trial. Transl Androl Urol. 2025https://pubmed.ncbi.nlm.nih.gov/40376518/ Lower Urinary Tract Symptoms Following Transurethral Resection of Prostate. Curr Urol Rep. 2018https://pubmed.ncbi.nlm.nih.gov/30128964/ 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol. 1998https://pubmed.ncbi.nlm.nih.gov/9628595/ The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladderhttps://www.auanet.org/guidelines-and-quality/guidelines/idiopathic-overactive-bladder BackTable Urology Episode 138: Hood-Sparing & Greenlight Laser Therapy in BPH Managementhttps://www.backtable.com/shows/urology/podcasts/138/hood-sparing-greenlight-laser-therapy-in-bph-management Dr. Bilal Chughtai, BackTable Urology contributor pagehttps://www.backtable.com/shows/urology/contributors/dr-bilal-chughtai Dr. Anjali Kapur, BackTable Urology contributor pagehttps://www.backtable.com/shows/urology/contributors/dr-anjali-kapur
---
BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app
By one estimate, half or more of all non-muscle invasive bladder cancer (NMIBC) is intermediate risk, yet the major guidelines still do not define it the same way, which leaves urologists sorting a large, mixed group of patients without a shared playbook for when to resect again, treat in the office, or start intravesical therapy. On this episode of BackTable Urology, Dr. Ruchika Talwar welcomes Dr. Wesley Yip, urologic oncologist at City of Hope, to rethink what she calls the forgotten stepchild of bladder cancer: intermediate-risk non-muscle invasive bladder cancer (NMIBC). Dr. Yip explains why he sees the category as a catch-all rather than a single biological entity, by his estimate covering 50 to 60 percent of NMIBC, why he now relies on the International Bladder Cancer Group (IBCG) definition, and why tumor grade comes first, ahead of multiplicity, size, and recurrence timing.
---
Get the BackTable apphttps://www.backtable.com/app
---
Timestamps
00:00 - Introduction02:24 - Defining Intermediate-Risk NMIBC07:53 - Case Presentation and the Initial TURBT10:42 - Evaluating the First Recurrence13:09 - High-Grade Cytology and Blue Light Cystoscopy15:01 - The Burden of Repeat TURBT16:57 - Office Fulguration and Chemoablation20:23 - Chemoablation Tolerability and Patient Selection24:24 - Intravesical Chemotherapy and Treatment Barriers28:08 - New Formulations and Upcoming Trials33:12 - Recurrence After Chemoablation and De-escalation38:00 - Future Directions and Patient-Centered Endpoints42:39 - Closing Remarks
---
More about this episode
Working through the case of a healthy 67-year-old man with recurrent low-grade Ta disease, the two discuss what to document at the first resection, how to counsel patients, when to return to the operating room, and when office fulguration, intravesical chemoablation, or intravesical chemotherapy with gemcitabine and docetaxel makes more sense. They cover the cumulative burden of repeat transurethral resection, practical lessons from bringing chemoablation into the clinic, how to read new trial data, and when to de-escalate surveillance. Dr. Yip closes with his hopes for the next five years: a biology-based definition and trials that measure fewer recurrences, fewer procedures, and better quality of life.
---
Resources
Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol. 2022https://pubmed.ncbi.nlm.nih.gov/35718695/ Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group. Eur Urol Oncol. 2025https://pubmed.ncbi.nlm.nih.gov/41076366/ All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. J Urol. 2022https://pubmed.ncbi.nlm.nih.gov/35770498/ Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guidelinehttps://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline EAU Guidelines on Non-muscle-invasive Bladder Cancerhttps://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer Bladder Cancer Advocacy Network (BCAN)https://bcan.org Dr. Wesley Yip, City of Hope physician profilehttps://www.cancercenter.com/physician-directory/wesley-yip Dr. Ruchika Talwar, BackTable Urology contributor pagehttps://www.backtable.com/shows/urology/contributors/dr-ruchika-talwar
---
BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app








